Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc (NYSE: CTLT) delivers essential pharmaceutical development solutions and manufacturing services for global healthcare partners. This dedicated news hub provides investors and industry professionals with timely updates on Catalent's operational milestones, strategic initiatives, and regulatory developments.
Access authoritative reporting on material events including clinical manufacturing advancements, drug delivery innovations, and global supply chain expansions. Our curated collection features earnings disclosures, partnership announcements, and facility updates directly impacting Catalent's market position.
Key focus areas include bioavailability enhancement technologies, commercial packaging solutions, and biologics manufacturing capabilities. Monitor critical updates through verified press releases and objective analysis of Catalent's role in accelerating therapeutic development timelines.
Bookmark this page for streamlined tracking of CTLT's progress in formulation science, regulatory submissions, and capacity investments across its global manufacturing network.
Catalent, a global leader in drug development and supply, announced the approval of its acquisition by Novo Holdings. At a Special Meeting, Catalent stockholders voted in favor of the Merger with 99.2% approval. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. Catalent's President and CEO, Alessandro Maselli, expressed gratitude for the stockholders' support and confidence in Catalent's future. The transaction, anticipated to close by the end of 2024, is subject to regulatory approvals and customary closing conditions. The transaction is not contingent on financing.
Catalent, Inc. reported third quarter fiscal 2024 results with a net revenue increase of 4% compared to Q3'23, excluding COVID-related revenue. The net loss decreased from $(227) million in Q3'23 to $(101) million in Q3'24. Adjusted EBITDA increased by 55% compared to Q3'23. Catalent's pending transaction with Novo Holdings is expected to close by the end of 2024.
